Eddy Pharmaceutical said that the imitation right of the new crown oral drug is in Longze Pharmaceutical, in which the company participates, and the company holds 4.76% of the equity of Longze Pharmaceutical. However, whether Longze Pharmaceutical produces a new crown generic drug business is not known at present.